Bosia A - Search Results

1

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells.

De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, Bosia A, Riganti C. De Boo S, et al. Among authors: bosia a. Mol Cancer. 2009 Nov 19;8:108. doi: 10.1186/1476-4598-8-108. Mol Cancer. 2009. PMID: 19925669 Free PMC article.

2

Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.

Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D, Bosia A. Riganti C, et al. Among authors: bosia a. Cancer Res. 2005 Jan 15;65(2):516-25. Cancer Res. 2005. PMID: 15695394

3

Na+/H+ exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin.

Miraglia E, Viarisio D, Riganti C, Costamagna C, Ghigo D, Bosia A. Miraglia E, et al. Among authors: bosia a. Int J Cancer. 2005 Jul 20;115(6):924-9. doi: 10.1002/ijc.20959. Int J Cancer. 2005. PMID: 15729714

4

Statins revert doxorubicin resistance via nitric oxide in malignant mesothelioma.

Riganti C, Orecchia S, Pescarmona G, Betta PG, Ghigo D, Bosia A. Riganti C, et al. Among authors: bosia a. Int J Cancer. 2006 Jul 1;119(1):17-27. doi: 10.1002/ijc.21832. Int J Cancer. 2006. PMID: 16450390

5

Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells.

Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Riganti C, et al. Among authors: bosia a. Mol Pharmacol. 2008 Aug;74(2):476-84. doi: 10.1124/mol.108.045286. Epub 2008 May 7. Mol Pharmacol. 2008. PMID: 18463201

6

RhoA silencing reverts the resistance to doxorubicin in human colon cancer cells.

Doublier S, Riganti C, Voena C, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, Bosia A. Doublier S, et al. Among authors: bosia a. Mol Cancer Res. 2008 Oct;6(10):1607-20. doi: 10.1158/1541-7786.MCR-08-0251. Mol Cancer Res. 2008. PMID: 18922976

7

Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.

Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. Among authors: bosia a. J Cell Mol Med. 2011 Jul;15(7):1492-504. doi: 10.1111/j.1582-4934.2010.01137.x. J Cell Mol Med. 2011. PMID: 20716130 Free PMC article.

8

A LDL-masked liposomal-doxorubicin reverses drug resistance in human cancer cells.

Kopecka J, Campia I, Olivero P, Pescarmona G, Ghigo D, Bosia A, Riganti C. Kopecka J, et al. Among authors: bosia a. J Control Release. 2011 Jan 20;149(2):196-205. doi: 10.1016/j.jconrel.2010.10.003. Epub 2010 Oct 12. J Control Release. 2011. PMID: 20946921

9

Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells.

Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. Riganti C, et al. Among authors: bosia a. Mol Pharm. 2011 Jun 6;8(3):683-700. doi: 10.1021/mp2001389. Epub 2011 May 5. Mol Pharm. 2011. PMID: 21491921

10

Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity.

Polimeni M, Voena C, Kopecka J, Riganti C, Pescarmona G, Bosia A, Ghigo D. Polimeni M, et al. Among authors: bosia a. Biochem J. 2011 Oct 1;439(1):141-9. doi: 10.1042/BJ20102016. Biochem J. 2011. PMID: 21679161

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters